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The blood vasculature regulates both the development and function of secondary lym-
phoid organs by providing a portal for entry of hemopoietic cells. During the development 
of lymphoid organs in the embryo, blood vessels deliver lymphoid tissue inducer cells 
that initiate and sustain the development of lymphoid tissues. In adults, the blood vessels 
are structurally distinct from those in other organs due to the requirement for high levels 
of lymphocyte recruitment under non-inflammatory conditions. In lymph nodes (LNs) 
and Peyer’s patches, high endothelial venules (HEVs) especially adapted for lymphocyte 
trafficking form a spatially organized network of blood vessels, which controls both the 
type of lymphocyte and the site of entry into lymphoid tissues. Uniquely, HEVs express 
vascular addressins that regulate lymphocyte entry into lymphoid organs and are, 
therefore, critical to the function of lymphoid organs. Recent studies have demonstrated 
important roles for CD11c+ dendritic cells in the induction, as well as the maintenance, 
of vascular addressin expression and, therefore, the function of HEVs. Tertiary lymphoid 
organs (TLOs) are HEV containing LN-like structures that develop inside organized 
tissues undergoing chronic immune-mediated inflammation. In autoimmune lesions, 
the development of TLOs is thought to exacerbate disease. In cancerous tissues, the 
development of HEVs and TLOs is associated with improved patient outcomes in several 
cancers. Therefore, it is important to understand what drives the development of HEVs 
and TLOs and how these structures contribute to pathology. In several human diseases 
and experimental animal models of chronic inflammation, there are some similarities 
between the development and function of HEVs within LN and TLOs. This review will 
summarize current knowledge of how hemopoietic cells with lymphoid tissue-inducing, 
HEV-inducing, and HEV-maintaining properties are recruited from the bloodstream to 
induce the development and control the function of lymphoid organs.
Keywords: blood vessels, high endothelial venules, peripheral node addressin, mucosal addressin, lymph nodes, 
tertiary lymphoid organs, ectopic lymphoid structures
iNTRODUCTiON
Secondary lymphoid organs (SLOs) are sites in which immune responses are initiated and main-
tained in order to generate protective immunity against exogenous pathogens and tolerance to 
self-antigens and commensal organisms (1, 2). These specialized structures include lymph nodes 
(LNs), Peyer’s patches (PPs), tonsils, appendix, bronchus-associated lymphoid tissue (BALT), 
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nasal-associated lymphoid tissue (NALT), isolated lymphoid 
follicles, and the spleen. All SLOs develop in the embryo, apart 
from NALT and BALT, which develop neonatally and in adults, 
respectively. As well as supplying oxygen and nutrients, the 
vasculature regulates the development of SLOs by recruiting 
a distinct population of hemopoietic cells that is essential to 
initiate lymphoid organogenesis. In adults, the blood vasculature 
in lymphoid organs is different from that found in other organs 
due to the requirement for efficient recruitment of lymphocytes 
under non-inflammatory, homeostatic conditions. Specialized 
blood vessels called high endothelial venules (HEVs) perform 
this function in all lymphoid organs except the spleen (3).
Tertiary lymphoid organs (TLOs) are lymph node-like 
immune cell clusters that develop inside non-lymphoid organs in 
response to chronic immune-mediated inflammation stimulated 
by persistent infections, chronic graft rejection, autoimmunity, 
and cancer (4). Defining features of TLOs are those that define 
SLOs: HEVs, lymphoid stromal cells, separate T-lymphocyte, 
and B-lymphocyte-rich compartments, follicular dendritic cell 
(FDC)-containing germinal centers, and antigen-presenting 
cells, including dendritic cells (DCs). However, in contrast to 
SLOs, TLOs are not encapsulated organs and are also known 
as tertiary lymphoid structures or ectopic lymphoid structures 
(ELS). TLOs are sites of active immune responses in autoimmune 
patients and animal models of autoimmunity (5, 6). There is evi-
dence implicating TLOs in generating destructive immunity to 
self-antigens (7) although the relative contributions of TLOs and 
SLOs to disease progression are difficult to dissect during ongo-
ing disease. Retrospective studies have correlated the presence of 
TLOs in resected solid cancers with prolonged patient outcome 
following resection of the primary cancer in several cancers (8). 
In some cancers, the density of HEVs alone predicted patient 
outcome (9, 10), indicating the critical role that HEVs play in 
orchestrating anti-cancer immunity. Importantly however, the 
formation of TLOs does not correlate with improved cancer 
patient outcome for all cancers. In virus-induced hepatic cellular 
carcinoma, TLOs promote carcinogenesis (11). In Helicobacter 
pylori-infected humans and mice, TLO development precedes 
carcinogenesis but whether TLOs promote the development 
of gastric cancer is not clear (12, 13). Therefore, there is much 
interest in how HEVs and TLOs develop and their exact roles in 
different chronic inflammatory diseases.
The development of LNs and PPs is well characterized, but 
how TLOs form is less clear because they develop during ongoing 
diseases. The similarities in structure between SLOs and TLOs 
suggest that underlying mechanisms driving their development 
may be conserved. Much attention has focused on the role of 
hemopoietic lymphoid tissue inducer (LTi) cells in driving the 
differentiation of local mesenchyme into lymphoid tissue organ-
izer (LTo) cells during the development of LNs and PPs in mice 
(14–16). LTo cells are gp38+ fibroblasts and are precursors of lym-
phoid stromal cells such as fibroblast reticular cells (FRCs) and 
FDCs. Lymphotoxin (LT)-αβ on hemopoietic LTi cells engaging 
lymphotoxin β receptor (LTβR) on LTo cells plays a dominant 
role in differentiating LTo into chemokine-secreting, adhesion 
molecule expressing fibroblasts that are able to recruit and retain 
LTis in the developing lymphoid tissue. An equally important, but 
unanswered question, is how embryonic blood vessels deliver LTi 
cells from their site of generation in fetal liver to predetermined 
sites where LNs are to develop. A role for inflamed blood vessels 
in initiating TLO development is implied by the finding that 
myeloid cells recruited into inflamed tissues drive the differen-
tiation of gp38+ fibroblasts that share properties with lymphoid 
stromal cells and are likely precursors of LTo cells (17). However, 
the mechanisms underlying myeloid cell recruitment by inflamed 
blood vessels were not determined in this study.
In adults, HEVs continually recruit naive and memory 
lymphocytes from the bloodstream into lymphoid organs in 
an antigen-independent manner where they survey DCs for 
cognate antigen (3). In peripheral LN draining the skin, HEVs 
express the peripheral addressin, peripheral node addressin 
(PNAd), whereas in PPs, HEVs express the mucosal addressin, 
mucosal addressin cell adhesion molecule (MAdCAM)-1. HEVs 
in some LNs (mesenteric, sacral, cervical) express both PNAd 
and MAdCAM-1. It has long been known that PNAd expres-
sion by HEV is actively maintained since PNAd levels on HEVs 
are rapidly downregulated following disruption of, or isolation 
from, the lymphoid microenvironment (18–20). Interestingly, 
HEVs in peripheral LN of newborn mice express the mucosal 
addressin but not the peripheral addressin (21, 22). During 
the first 2–3  weeks of life, HEV maturation is completed by a 
switch in vascular addressin expression from MAdCAM-1 to 
PNAd. How the vascular addressin switch is regulated and PNAd 
expression maintained on HEV in adult SLOs have been unclear. 
Recent studies have identified critical roles for CD11c+ DCs in 
the vascular addressin switch (23) as well as the maintenance of 
PNAd-expressing HEV in adult mice (24). Therefore, the blood 
vasculature plays a central role in recruiting distinct populations 
of hemopoietic cells at precise stages of lymphoid organ develop-
ment that are essential to initiate lymphoid organogenesis, induce 
HEV maturation, and maintain fully differentiated HEV. These 
points will be addressed in greater detail in the following section.
A key step in the recruitment of lymphoid cells is their selec-
tion from the total pool of blood-borne leukocytes by binding 
to the inner blood vessel surface prior to transmigration across 
the vessel wall and entry into lymphoid organs. This involves a 
sequence of adhesive interactions between leukocytes and vascu-
lar endothelial (VE) cells, which can be divided into distinct stages 
of rolling and activation-induced arrest. In general, selectins 
mediate rolling and chemokines immobilized on the endothelial 
cell (EC) surface activate leukocyte integrins to arrest rolling 
cells. How hemopoietic cells with LT-inducing, HEV-inducing, 
and HEV-maintaining properties are recruited into lymphoid 
organs is central to understanding both the development of lym-
phoid tissues and the mechanisms regulating adaptive immune 
responses and disease pathologies.
BLOOD veSSeLS AND THe 
DeveLOPMeNT OF SLOs
The earliest event in LN development is the formation of 
lymphatic vasculature around embryonic day 10.5 (E10.5) by 
budding from larger veins and establishing a primordial lymph 
sac or anlagen (Figure  1) (25). CD45+ CD4+ CD3− IL7Rα+ 
FiGURe 1 | Blood vessels and high endothelial venules (Hevs) in the development of lymph nodes (LNs). Top: LN development represented as relative 
sizes of (left) embryonic and (right) neonatal and adult LNs. Middle (left): in the embryo, neuronal stimulation induces retinoic acid-dependent expression of CXCL13 
by mesenchymal cells that can be reverse transcytosed and presented on the inner surface of embryonic blood vessels. (Right) In LNs of adults, the HEV network 
extends from the cortical/paracortical junction adjacent to B cell follicles to large collecting veins in the hilar region gradually increasing in diameter from the smallest, 
order V venules to the largest order I venules (left hand inset). HEV connect directly to afferent lymphatics via fibroblast reticular cell-coated conduits that form the 
supporting internal scaffold on which lymphocytes and antigen presenting cells crawl during  immunosurveillance (right hand insert). This enables the recruitment of 
fetal liver-derived CXCR5+ α4β7 integrin-expressing lymphoid tissue inducer cells to the sites where LN develop. (Right) At birth, structurally distinct MAdCAM-1-
expressing HEV lined with cuboidal endothelial cells and supported by a thickened fibronectin containing basal lamina are visible. During the first weeks of life, 
MAdCAM-1-expressing HEV recruit CD11c+ neonatal migratory dendritic cells mobilized from the intestinal lamina propria, undergo a switch from MAdCAM-1 to 
peripheral node addressin expression and become ensheathed by fibroblast reticular cells. The vascular addressin switch is followed by rapid growth and a 
concomitant increase in cellularity and expansion in LN.
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RORγt+, Id2+ lymphoid tissue-inducing (LTi) cells (members 
of the group 3 category of innate lymphoid cells) are recruited 
into the anlagen and drive the development of gp38+ LTo cells 
from local mesenchyme (26). CXCL13 and IL7, produced by 
local mesenchymal fibroblasts in response to retinoic acid (RA) 
generated by neuronal stimulation, recruit CXCR5 and IL7 
receptor-expressing LTi cells at sites where LNs are to develop 
(14). In the embryonic intestine, myeloid cell expression of the 
tyrosine kinase receptor, RET, is important to localize LTi to sites 
where PPs develop (27). LTαβ is upregulated on the surface of 
incoming LTis and stimulates LTβR-dependent upregulation of 
MAdCAM-1, vascular cell adhesion molecule (VCAM)-1, and 
intercellular adhesion molecule (ICAM)-1 and the secretion of 
homeostatic chemokines CXCL13, CCL19, and CCL21 by lym-
phoid stromal LTo cells. This enables LTo cells to retain recruited 
LTi cells in the developing anlagen. The continual recruitment 
and retention of LTi cells during embryogenesis is required to 
differentiate sufficient numbers of LTo cells to support the full 
development and organization of LNs and PPs (22).
During embryogenesis, LTi cells are generated in the fetal 
liver so how are they recruited to the sites at which LNs and PPs 
are to develop? A key finding is that all embryonic venous blood 
vessels express MAdCAM-1 (28). LTis express the integrin α4β7, 
which binds to MAdCAM-1 and α4β7-MAdCAM-1 binding is 
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a dominant pathway for leukocyte recruitment from the blood-
stream into developing LNs (21). In adults, homeostatic and 
inflammatory chemokines released by stromal cells are reverse 
transcytosed and presented on the inner blood vessel surface 
using Duffy antigen-related receptor-dependent and independ-
ent pathways (29–32). By analogy, CXCL13 released by activated 
fibroblasts presented on the inner surface of embryonic blood 
vessels together with cell surface MAdCAM-1, recruits CXCR5 
expressing LTis from the bloodstream to initiate lymphoid 
organogenesis. Key questions, therefore, are what controls 
MAdCAM-1 expression on blood vessels in the embryo and is 
MAdCAM-1 essential for lymphoid organogenesis? MAdCAM-1 
is expressed by all venous blood vessels as early as E9.5 in mice 
and expression is maintained throughout lymphoid organo-
genesis (28). In adults, MAdAM-1 expression by cultured EC is 
induced by classical Rel A/NF-κB signaling stimulated by factors 
such TNF-α, LT-α, IL-1-β, and LPS (33–35). Whether constitu-
tive MAdCAM-1 expression on blood vessels in the LN anlagen 
is driven by NF-κB signaling or is ontologically determined, for 
example, by the transcription factor NKX2.3 (36), has not been 
determined. Interestingly, MAdCAM-1 expression by embry-
onic blood vessels is not essential for lymphoid organogenesis 
since LNs and PPs develop in MAdCAM-1 ko mice (37). LTis 
also express α4β1 integrin, which binds to VCAM-1 and could 
substitute for MAdCAM-1, however, mice globally deficient in 
VCAM-1 die in utero (38) and the role of VCAM-1 in lymphoid 
organogenesis is undetermined. ICAM-1 expression by LTo cells 
is not essential for lymphoid organogenesis since LNs develop in 
ICAM-1-deficient mice (39). However, MAdCAM-1, VCAM-1, 
and ICAM-1 are not redundant in adult mice because they regu-
late lymphocyte recirculation through SLOs and/or recruitment 
to inflamed tissues (1, 3).
Lymph nodes and PPs do not develop in LTα ko mice (40). 
Administration of an LTβR agonist to pregnant mice bypasses the 
requirement for LTi cells and induces LN development (41). The 
initiation of LN and PP organogenesis is time restricted; mesen-
teric LN starts around E9–10 and PPs around E16 with peripheral 
LN (axillary, brachial, inguinal, and popliteal) between E10 and 
E16. However, exogenous administration of LTβR agonists out-
side of these times will not initiate LN formation. Administration 
of antagonistic LTβR-Ig to pregnant wildtype mice also blocks 
the development of LN in a similar time-dependent manner (42). 
What controls the timing of LN development is not clear but one 
possibility is the ability of embryonic blood vessels to recruit 
LTi cells. For example, the expression of sufficient MAdCAM-1, 
immobilized chemokines, or other, as yet unidentified, homing-
associated molecules that recruit LTi cells from the bloodstream 
into to the LN anlagen may be time dependent. The local genera-
tion of RA drives lymphoid organogenesis and RA is required to 
mature developing blood vessels in the embryo (43). It is possible 
that locally generated RA facilitates LTi recruitment by promot-
ing the expression or activity of homing-associated molecules on 
growing vessels in the LN anlagen, but we know very little about 
when RA is produced and how this is regulated.
Although LTαβ–LTβR is a dominant NF-κB signaling path-
way and CXCL13 a dominant chemokine in the development of 
peripheral LN and PP, other pathways can substitute during the 
development of mucosal and visceral draining LN. For example, 
mesenteric, cervical (submandibular), sacral, and lumbar LN (44) 
develop in LTβ-, LTβR-, or CXCL13-deficient mice (15, 22). LTβR 
engagement by membrane LTαβ stimulates both classical NF-κB 
signaling via Iκκβ and p50/RelA as well as non-classical signal-
ing via Iκκα and p52/RelB, and there is considerable interplay 
between these two pathways (45). LN and PP do not develop in 
mice globally deficient in either RelA or Rel B, key components 
of classical and non-classical NF-κB signaling, respectively, 
although the impact of classical NF-κB signaling on LN develop-
ment may be via upregulation of non-classical NF-κB signaling 
substrates such as NF-κB2 and RelB (46, 47). In mice deficient 
in NFkB2, the substrate for p52 in the non-classical pathway, 
mesenteric and some peripheral LN develop but lymphoid organs 
that form later in embryogenesis (inguinal, popliteal, and PPs) are 
small or do not develop at all (48). It is suggested that p50/RelB 
can substitute for p52/RelB in these mice but the signal strength 
is weaker and so, although LTi cells are recruited, the induction 
of CAMs is not enough to retain sufficient LTi cells to maintain 
development and organize the full structure of late developing 
lymphoid organs. Non-classical NF-κB signaling is important 
for the proper development of HEVs since the small LN that 
develop in LTβ- or NFkB2-deficient mice have poorly developed 
HEVs, as do peripheral LNs that develop in mice expressing a 
signaling-deficient mutant of the non-classical NK-κB pathway, 
Iκκα (48, 49). The widespread expression of LTβR on the develop-
ing vasculature as well as LTo cells makes it difficult to assess their 
relative contributions to the development of lymphoid organs 
or of HEVs in mice globally deficient in either LTαβ–LTβR or 
following administration of antagonistic LTβR-Ig. Recent studies 
have shown that the development of peripheral LNs in 25–40% of 
pups is completely blocked in mice selectively deficient in LTβR 
in blood and lymphatic ECs, but the underlying mechanism is 
not clear (50). Further work will be required to dissect the roles of 
NF-κB signaling in the blood vs the lymphatic vasculature during 
lymphoid organogenesis and how this integrates into the scheme 
of lymphoid organogenesis driven by gp38+ lymphoid stromal 
LTo cells.
THe DeveLOPMeNT AND FUNCTiON OF 
HiGH eNDOTHeLiAL veNULeS iN SLOs
The vascular Addressin Switch
The recruitment of naïve T and B cells into all lymphoid organs, 
apart from spleen, is dependent on the differentiation of a subset 
of blood vessels into HEVs. Structurally distinct HEVs are not 
apparent in LN of mice until birth when a branching network 
of HEV blood vessels starts to organize around B cell follicles 
during the first days after birth in PPs (28). A key event in 
neonatal maturation and expansion of LN is a switch in vascular 
addressin expression by HEV (21). In LNs of newborn mice, 
all HEVs express the mucosal addressin MAdCAM-1; during 
the first few weeks of life MAdCAM-1 is downregulated and 
expression of the PNAd is upregulated. PNAd comprises a mix-
ture of ligands for L-selectin (CD34, podocalyxin, GlyCAM-1, 
MAdCAM-1, nepmucin, and endomucin) that are modified 
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by 6-sulfo sialyl Lewisx on extended core 1 O-linked oligosac-
charides and detected by monoclonal antibody MECA79 (51). 
PNAd expressed on the inner, apical surface of HEVs co-operates 
with the arrest chemokine CCL21 to select L-selectin/CD62L+, 
CCR7+ lymphocytes from the bloodstream for entry into LN 
allowing postnatal colonization of LN by naive T and B lympho-
cytes as they are released into the circulation from the thymus 
and fetal liver/bone marrow, respectively. Interestingly, PNAd is 
also expressed on the basolateral surfaces of ECs lining HEVs 
but it is not involved in recruiting lymphocytes directly from 
the bloodstream. Distinct sulfotransferases generate apical and 
basolateral PNAd and the expression of GlcNAc6ST-2 (HEC-6ST; 
CHST4), which is required to generate apically expessed PNAd, 
is restricted to HEV ECs, whereas GlcNAc6ST-1 (CHST2), which 
generates basolaterally expressed PNAd, is more widely expressed 
in stromal cells (51). The PNAd-expressing HEV network grows 
alongside the growth of other stromal components resulting in 
a rapid increase in the size and cellularity of LN during the first 
weeks of life (23). Although PNAd is a well-characterized ligand 
for L-selectin, it only accounts for 50% of L-selectin-dependent 
recruitment into peripheral LNs. Important non-PNAd ligands 
on HEV that regulate L-selectin-dependent recruitment into 
peripheral LN include 6-sulpho sialyl Lewis X modified N-linked 
glycans such as CD34, as well as a minor role for core 2-branched 
O-linked glycans (51, 52).
Vascular addressins expressed on the inner, luminal surface 
of ECs lining HEV bind to homing receptors on lymphocytes; 
therefore, addressins define the specialized property of HEV 
in driving lymphocyte recruitment into LNs and PPs. PNAd 
was originally described in HEVs of peripheral LNs draining 
the skin (inguinal, axillary, brachial, and popliteal) (53) and 
MAdCAM-1 in mucosal-associated lymphoid tissues such as PPs 
(54). However, analysis of other mucosal and viscera-draining 
SLOs in mice shows that PNAd expression is upregulated and 
MAdCAM-1 variably downregulated. For example, MAdCAM-1 
expression is not completely downregulated in mesenteric and 
sacral LNs where individual high endothelial cells (HECs) co-
express PNAd and MAdCAM-1. However, mucosal addressin 
is completely downregulated in lymphoid tissues draining other 
mucosal sites such as cervical (submandibular) LN or NALT 
(4). Similarly, LNs draining visceral organs, such as lumbar LN, 
express PNAd and not mucosal addressin (44); therefore PNAd 
expression is not restricted to subcutaneous LN and is widely 
expressed by mucosal and visceral LN in mice. PNAd expression 
was originally reported to be restricted to the basolateral surfaces 
of HEVs in PPs (54). However, in different mouse strains and 
other species, PNAd expression in PPs is comparable with that in 
peripheral LN, which may reflect increased antigenic stimulation 
(51). Why MAdCAM-1 expression is maintained by HEVs in PPs 
and some mucosal LN whereas other HEVs completely switch 
to PNAd expression is not clear, but MAdCAM-1 expression is 
regulated by the transcription factor NKX2.3 (55).
The Connection with Afferent Lymph
A unique feature of HEV is the connection with afferent lymph. 
HEVs are supported by a perivascular sheath composed of FRCs 
that are connected to the FRC coated conduit system within LN. 
The conduit system allows communication between afferent 
lymph and HEV whereby incoming lymph-borne soluble factors, 
such as chemokines and cytokines, are delivered directly to the 
basal lamina of HEV (Figure 1) (56). Early studies showed that 
ligation of afferent lymphatics, which drain fluid and immune cells 
into popliteal LN, resulted in a gradual flattening of HECs and 
although some PNAd expression was retained it was restricted 
to the basolateral surfaces of HECs (18, 19, 57). Other changes 
in HECs included a transient induction of MAdCAM-1 expres-
sion, which peaked 4 days following deafferentization suggesting 
reversion of mature HEVs to an immature state. Lymphocyte 
recruitment by HEV decreased and was no longer detectable 
8 days after deafferentization. HEVs reverted to fully functional 
vessels expressing PNAd at the luminal surface following regrowth 
of afferent lymphatics demonstrating the complete reversibility of 
HEV differentiation. Early studies indicated a dominant role for 
LTβR signaling in maintaining PNAd expression since chronic 
administration of LTβR blocking reagents to adult mice recapitu-
lates the effects of deafferentization in that HEVs downregulate 
PNAd and MAdCAM-1, and therefore lose the ability to support 
lymphocyte homing (58). The flattened appearance of PNAd-
positive HEV in deafferentized LNs is seen in peripheral LNs 
that develop in mice in the absence of endothelial expression of 
LTβR (50) and in inguinal LNs developing in the absence of either 
NFKB2 or IKKα (48, 49), indicating a key role for LTβR stimulated 
non-canonical NFκB signaling in driving luminal expression of 
PNAd by HECs. Which cells engage LTβR on HECs to induce 
and maintain PNAd expression has been unclear, however, recent 
studies identify dominant roles for CD11c+ DCs in the induction, 
as well as the maintenance, of PNAd expression by HEV.
Role of CD11c+ Cells in the vascular 
Addressin Switch
An important finding is that during the first weeks of life CD11c+, 
CD11b+, CD103+ DCs mobilized from the gut lamina propria 
in response to microbial colonization induce the switch from 
mucosal to peripheral addressin expression by HEV in peripheral 
LN (23). RA-dependent signaling is critical for these so-called 
neonatal migratory DCs to induce the vascular switch; cells that 
do not express retinaldeyhde dehydrogenase (RALDH), which 
generates RA from retinaldehyde, a derivative of Vitamin A, are 
unable to induce the vascular addressin switch. This important 
finding came from studies of adult germ-free mice in which 
peripheral LN HEVs express MAdCAM-1, but not PNAd, and 
LN are small without clear compartmentalization into T and 
B-cell areas, similar to LN in newborn mice. When germ-free 
mice were co-housed with conventionally housed mice, HEVs 
underwent the vascular addressin switch with consequent 
increases in lymphocyte homing and LN cellularity. These effects 
could be reproduced by administration of RALDH+ neonatal 
migratory DCs isolated from conventionally housed adult mice 
to young germ-free mice. Migration of neonatal migratory DCs 
to peripheral LN was dependent on MAdCAM-1 expression by 
HEVs in peripheral LN. Interestingly, the migration of these 
cells to peripheral LN was highest around 2  weeks after birth 
and subsided after 6  weeks, presumably because of the loss of 
MAdCAM-1 expression by peripheral LN HEVs.
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In adult mice, CD11c+ cells have been shown to maintain 
PNAd-expressing, fully functional HEVs by stimulating LTβR-
dependent signaling in HECs (24, 50). Moussion and Girard 
used transgenic mice expressing the diphtheria toxin (DT) 
receptor under the CD11c promoter (CD11c-DTR mice) and 
DT to deplete CD11c+ cells (24). They noted a gradual loss of 
PNAd expression, a transient expression of MAdCAM-1, and a 
reduction in lymphocyte entry via HEVs over 8 days, which was 
prevented by administration of exogenously generated LTαβ-
expressing CD11c+ DCs. Since ligands for LTβR are membrane 
bound, LTαβ DCs might be expected to make frequent contacts 
with HECs under homeostatic conditions in order to maintain 
PNAd expression. Migration of DCs into LN of adult mice has 
focused on entry from surrounding tissues via incoming, afferent 
lymphatics. DCs entering via this route do not come into cellular 
contact with HECs since they do not penetrate the surrounding 
pericytic sheath (59, 60). However, DCs entering from sur-
rounding tissues via afferent lymphatics do locate around HEVs 
(61); it is therefore possible that protruding DC membranes or 
exosomes released by DC (62, 63) could cross the pericytic sheath 
and contact with HECs. Precursors of classical DCs that are 
recruited from the bloodstream into LN of adult mice spend up 
to 5 h in the walls of HEVs are a possible HEV-maintaining cell. 
In this scenario, the critical role of afferent lymph in maintaining 
fully differentiated HEVs is not as an entry point for DCs but to 
supply the chemoattractants necessary to recruit LT-expressing 
DCs from the bloodstream, enabling DC-HEC contact to sustain 
LTβR signaling.
Interestingly, CCR7+ expression by CD11c+ cells is required 
to control the homeostatic expansion of PNAd-expessing HEV 
but in the absence of CCR7 expession, CD11c+ cells are still able 
to induce the switch in addressin expression to PNAd (64). The 
increase in size of the HEV network and associated increase 
in LN cellularity and volume is due, in part, to the release of 
angiogenic stimuli such as VEGF-A by FRC and DCs (65, 66). 
These findings suggest that the differentiation of fully functional, 
PNAd-expressing HEV and the expansion of the HEV network 
are controlled by different types of CD11c+ cells in adult mice. It 
will be interesting to determine whether RA signaling is required 
for CD11c+ DCs to maintain PNAd expression and expand HEV 
in adult mice as has been shown in neonates (23).
High endothelial venules in Homeostatic 
Lymphocyte Trafficking
Together, the SLOs are uniquely placed to survey the whole 
body for incoming pathogens and self-antigens derived from 
the skin, mucosal surfaces, or directly into the bloodstream, 
mount an appropriate immune response and clear invading 
pathogens from the body. To achieve this, rare lymphocytes with 
appropriate antigen receptor must be selected from the total 
pool of lymphocytes each with its own unique receptor; this 
occurs inside SLOs. Pathogens are first degraded and presented 
as MHC-binding peptides on DCs bound to gp38+ FRCs. The 
total pool of lymphocytes in the body is then exposed to patho-
gen peptide-enriched DCs. Lymphocytes with antigen receptors 
able to respond to the level of peptide presented are removed 
from the circulating pool of cells and undergo proliferation and 
differentiation to effector, memory, or regulatory lymphocytes 
before returning to the circulation. Blood vessels are critical 
components of adaptive immunity since they recruit naïve and 
central memory lymphocyte irrespective of antigen receptor 
specificity and deliver them to DCs inside lymphoid organ under 
homeostatic conditions. Postcapillary venules (PCV) lined with 
continuous ECs are the preferred sites of lymphocyte extravasa-
tion in LNs and other organs such as the skin and GI tract. The 
increase in diameter as blood vessels transition from capillaries 
to PCV alters hemodynamics such that leukocytes move to the 
outer stream or margin of flowing blood adjacent to the inner 
surface of the vessel (67). Here lymphocytes tether, roll, and arrest 
on the inside surface without obstructing flow that would happen 
in smaller capillaries. In other organs where the microvessels are 
lined with sinusoidal endothelium, such as the spleen, liver, and 
bone marrow, shear stress at the vessel wall–blood interface may 
be significantly reduced that the requirement for selectins for 
capture from flowing blood is not necessary and other homing-
associated molecules such as leukocyte integrins perform this 
role (67). In LNs and PPs, the trafficking of naïve lymphocytes is 
restricted to specialized postcapillary venules called HEVs. These 
vessels are structurally adapted to support large-scale lymphocyte 
trafficking without compromising vascular integrity. The spleen 
does not have HEV and, in mice, lymphocytes enter the spleen 
from capillaries in the marginal zone using incompletely defined 
molecular recognition pathways. The structure of human spleen 
differs from that in mice and the route of lymphocyte entry has 
not been identified (68).
Arteries feeding the LN enter at the hilar region and arborize 
into nutrient- and oxygen-transporting capillary beds surround-
ing B cell follicles in the outer cortex and in the T cell zone. 
The capillary beds lead directly (or indirectly via arteriovenous 
shunts) into the postcapillary venular network, which extends 
throughout the paracortex (T cell area) of the LN; HEVs form 
part of this postcapillary network (Figure 1). HEVs are readily 
distinguished from other blood vessels; the cuboidal (high) ECs, 
which line HEV and give these vessels their name, contrast with 
flat ECs lining other vessels. In addition, HEVs are supported by 
a thickened basal lamina comprising overlapping pericytes and 
a perivascular sheath of FRC that together generate a structural 
and functional unit exquisitely adapted to support high levels 
of lymphocyte recruitment and transendothelial migration 
to deliver lymphocytes to the LN parenchyma. The ECs lining 
HEVs express a number of pan-endothelial markers such as 
VE-cadherin and CD31 as well as the master venous regulator 
Nr2f2 (69), which suggests that they differentiate from local post-
capillary venules. Invitavital imaging of lymphocyte recruitment 
allows HEVs to be ordered according to size and location. The 
smallest vessels (order V) are found at the junction between the 
B cell-enriched cortex and the T cell-enriched paracortex. HEVs 
gradually increase in size to larger vessels (order II) at the junction 
between the paracortex and medulla where they merge into order 
I collecting venules which drain into hilar vein (70) (Figure 1). 
The majority of lymphocytes recruited into LN and PPs are 
from the higher order vessels III–V. In peripheral LN, L-selectin 
dependent recruitment from lower order vessels does occur but 
the vascular ligand on HEC is distinct from PNAd (71). How this 
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complex branching network of differentiated HEVs develops and 
is maintained in LN is not clear but it is likely to be connected 
with development of the highly organized secondary structures 
of FRC-coated conduits that connect the draining lymphatics 
with the HEVs (29). The dominant roles of LTβR signaling in 
maintaining fully differentiated PNAd-expressing HEVs as well 
as T/B compartmentalization in LNs are likely to cooperate in 
forming an organized HEV network.
The ability to image the behavior of leukocytes inside post-
capillary venules using intravital microscopy has identified the 
molecular interactions between lymphocytes and HEVs in LN 
and PPs that control recruitment from flowing blood. The multi-
step adhesion cascade describes the sequence of tethering, rolling 
and activation-induced arrest, which selects lymphocytes for 
transendothelial migration and entry into lymphoid organs. The 
cascade is best exemplified by the fact that neutrophils undergo 
L-selectin-depending rolling in HEVs but they are unable to 
undergo activation-induced arrest by CCL21 immobilized on the 
inner HEV surface because they do not express CCR7 and are, 
therefore, not recruited into LN under homeostatic conditions 
(70). The selectin, chemokines, and integrins that regulate roll-
ing and activation-induced arrest of naive and central memory 
T and B cells and the non-random recruitment of T and B 
lymphocytes in HEV of LN and PP of mice have been described 
in detail elsewhere (1, 3, 72–74). The regulated expression of 
peripheral node and mucosal addressins by HEV and their roles 
in lymphocyte recruitment are conserved in LNs of larger animals 
as well as humans indicating that studies in mice have clinical 
relevance (75–79). This review will summarize recent advances 
in understanding the structure and function of HEV and its role 
in regulating adaptive immunity.
In LNs, L-selectin mediates tethering and rolling of lympho-
cytes. In comparison with T cells, B cells express lower L-selectin 
and are reduced in LNs but highly enriched in PPs. Although 
L-selectin supports lymphocyte rolling in HEVs of PPs, it is not a 
dominant homing molecule under homeostatic conditions since, 
in contrast to peripheral LN, the cellularity of PPs in L-selectin 
deficient mice is not reduced (80). The B-cell expressed lectin that 
supports preferential recruitment by HEVs of PPs was unknown 
until a detailed comparison of transcriptomes expressed by HECs 
isolated from PPs and peripheral LN of mice demonstrated 
preferential expression of the enzyme β-galactoside α-2,6-
sialyltransferease I (ST6GaI 1) by PP HECs. ST6Gal 1 generates 
high affinity α-2,6-sialylated glycan ligands for the B cell lectin 
CD22 (Siglec-2) and was shown to function as a B cell selective 
mucosal addressin in PPs (69).
Apart from addressin expression and their location inside 
LN, a characteristic histological feature of HEV is lymphocytes 
embedded in the walls of HEV, which suggests that transmigra-
tion is a rate-determining step in lymphocyte recruitment from 
the bloodstream into the LN parenchyma. Transmigration is 
a rapid event taking 3  min to cross the endothelial lining and 
10 min to complete migration across the underlying basal lamina 
(81–83). The molecules and signaling pathways that regulate 
transmigration are not completely understood. Whether lym-
phocytes move through the junctions between HECs (paracel-
lular route) or penetrate the EC cytoplasm (transcellular route) 
has long been debated (84, 85). It is important to understand how 
lymphocytes transmigrate the walls of HEV since the potential 
for bi-directional signaling in lymphocytes and HECs may prime 
transmigrating lymphocytes for interstitial motility and immuno-
surveillance. Recent studies have demonstrated that lymphocytes 
are held in the so-called HEV pockets that are extracellular spaces 
between HECs and the surrounding pericyte-containing basal 
lamina (86). The accumulation of transmigrating lymphocytes, 
particularly T cells, contributes to the height of HECs (81, 87). 
Residence in HEV pockets provides an opportunity for cellular 
contacts with HECs or with other transmigrating cells, such as 
DCs, which may facilitate rapid transmigration in comparison 
with vessels lined with flat EC (81). It is also possible that antigen 
could be passed from the basolateral adjoining conduits to DCs 
inside HEV pockets for presentation to incoming lymphocytes. 
HEVs are contractile vessels responding to locally released 
vasoactive agents (88). Arterial pressure and vasoconstriction 
can regulate the height of HECs measured in histological sec-
tions of LN (89). Dynamic changes in shear stress at the vessel 
wall interface generated by HEV contractility may enhance the 
capture of lymphocytes from flowing blood.
Lymphocytes form very close, intercellular, gap-like junc-
tions of 2–4 nm with HECs during transmigration (90), which 
may be the in vivo equivalent of the docking structures between 
lymphocytes and ECs reported in vitro (91, 92). ECs lining HEVs 
express a range of junctional proteins that are found in other 
vascular beds, including VE-cadherin, CD31, JAM-A, JAM-B, 
JAM-C, and ESAM-1 (93). Engagement of EC junctional pro-
teins by complementary receptors on lymphocytes may regulate 
migration across the endothelial lining of HEVs, as shown for 
leukocytes transmigrating inflamed blood vessels (67). Unlike 
other types of endothelium, HEV ECs lack tight junctions and 
vascular specific claudin-5. These distinct structural features 
may facilitate paracellular transmigration of lymphocytes and/or 
lymphocyte accumulation inside HEV pockets.
Some progress has been made in dissecting the molecular 
events driving entry and exit of lymphocytes from HEV pockets 
and subsequent penetration of the underlying basal lamina to 
enter the LN parenchyma (94). Lymphocytes are retained in HEV 
pockets of FTY720 treated mice, and this was thought to be due 
to lack of space in the LN parenchyma (86). However, as well as 
blocking lymphocyte exit from LN via lymphatics, FTY720 inhib-
its T cell recruitment from the bloodstream across HEVs (95). An 
alternative explanation is that incoming T cells drive the exit from 
HEV pockets and, in the absence of incoming T cells in FTY720 
treated mice, lymphocytes do not complete transmigration, as has 
been shown in vitro (96). There are other mechanisms controlling 
lymphocyte retention in HEV pockets. T cells accumulate in the 
endothelial lining of HEVs in mice treated with dual specificity 
MMP/ADAM inhibitors (87), suggesting that exit from HEV 
pockets may be metalloproteinase-dependent. L-selectin is 
proteolytically cleaved from T cells as they transmigrate HEVs 
(97) and lymphocytes expressing a metalloproteinase-resistant 
mutant of L-selectin take longer to transmigrate the endothelial 
lining of HEVs (98). Proteolytic shedding of L-selectin following 
cross-linking by basolaterally expressed ligands such as PNAd 
may polarize transmigrating T cells, as recently demonstrated in 
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monocytes (99) and neutrophils (100) and allow directed migra-
tion into the LN parenchyma in response to HEC-derived lipids 
such as autoaxin and lymphoid stromal cell-derived chemokines 
such as CCL19 and CCL21 (101, 102).
The impact of immunization and infection 
on High endothelial venules
There are marked changes to HEVs in LNs draining sites of 
immunization or infection. These include increased blood flow, 
expansion of the HEV network, and marked changes in expres-
sion of homing-associated molecules. Changes in HEV function 
cooperate to alter the size and composition of the leukocyte 
infiltrate. In particular, altered expression of homing molecules 
on HEV enables the recruitment of activated lymphocytes and 
innate immune cells that are normally excluded by HEVs because 
they lack expression of L-selectin or CCR7. The impact of altered 
immune cell recruitment via HEV on ongoing immunity is only 
just starting to be analyzed (94).
Innate immune cells remodel feeding arterioles to increase 
blood supply and, thereby, increase the delivery of naïve lympho-
cytes into draining LNs (103). This allows a major fraction of the 
full repertoire of lymphocytes to pass through antigen-activated 
LNs within a few days (104). The HEV network grows to accom-
modate the increase in blood supply and the accompanying 
increase in lymphocyte trafficking. For example, the total length 
of HEVs increases threefold from approximately 10–30  cm in 
antigen-reactive LN in parallel with a threefold size increase of LN 
volume (105). LT and VEGF family members regulate expansion 
of the HEV network. LTβR activation of FRCs by DCs induces 
release of VEGF-A, an angiogenic factor that stimulates HEV 
growth (65, 106). VEGF-A is also produced by activated DCs, 
which, following injection into the skin, stimulate the growth of 
HEV in LN draining the site of injection (66).
Other changes to HEV in antigen-challenged LN relate directly 
to links with afferent lymphatics. For example, the plasticity of 
HEV revealed by afferent lymphatic ligation (19) or isolation 
from the LN environment (20) is directly relevant to adaptive 
immune responses. Antigen administration is accompanied by a 
temporary shutdown of afferent lymphatics between days 2 and 
5 and concomitant dedifferentiation of HEV (107). Interestingly, 
the loss of luminal PNAd by HEV following antigen administra-
tion is accompanied by transient induction of MAdCAM-1 as 
found following deafferentization or CD11c+ cell depletion. By 
limiting the influx of lymphocytes, the loss of PNAd expres-
sion may serve to prevent the dilution of lymphocytes already 
in contact with antigen-laden DCs and promote the generation 
of memory cells. The reversion of PNAd-expressing HEV to 
MAdCAM-1-expressing HEV may allow entry of LTis or other 
α4β7 integrin-expressing innate lymphoid cells (108), for repair 
or remodeling of LN during the later stages of virus infection to 
restore preinfection architecture (109).
Vascular changes in antigen-stimulated LNs are accompanied 
by increased growth of afferent lymphatics and remodeling of the 
FRC network that alters the availability of chemokines for pres-
entation by HEVs. For example, the dramatic reduction in CCL21 
and CXCL13 expression by LN stroma following viral or bacte-
rial infection (110) impacts on T and B lymphocyte recruitment 
since stromal cell-derived chemokines are presented by HEVs to 
blood-borne lymphocytes (32). The increased delivery of DCs 
and other immune cells mobilized from inflamed tissues via 
expanded afferent lymphatics may have, as yet unexplored, effects 
on HEV function. However, as the immune response subsides, 
CD11c+ cells are required to remodel the perivascular FRC sheath 
surrounding HEVs and restore vascular permeability and HEV 
function (111). These observations suggest a regulatory loop 
based on HEV that controls the size of LN, preventing uncon-
trolled growth of inflamed lymphoid tissue. How the structure 
of LNs and other secondary lymphoid tissues is restored to the 
preactivated state is largely unknown. This is likely to be relevant 
to understanding TLOs that develop in chronically inflamed 
tissues.
BLOOD veSSeLS, HiGH eNDOTHeLiAL 
veNULeS, AND THe DeveLOPMeNT OF 
TLOs
Tertiary lymphoid organs or ELS develop inside non-lymphoid 
organs. TLOs form in response to chronic immune-mediated 
inflammation stimulated by persistent antigens such as infection, 
allograft rejection or ulcerative colitis but also in several autoim-
mune conditions such as rheumatoid arthritis and Hashimoto’s 
thyroiditis (112). TLOs have been reported by histology in biop-
sied or surgically removed clinical tissues from the majority of 
organs in the body including the CNS and atherosclerotic aorta. 
TLOs are also found associated with cancerous tissues. TLOs are 
highly organized lymph node-like structures containing discrete 
T and B-cell rich areas supported by stromal cells that share mark-
ers with FRCs and FDCs in LNs. TLOs contain PNAd-expressing 
blood vessels that resemble structurally distinct HEV in LNs; 
they are the presumed sites of entry of blood-borne lymphocyte 
and, therefore, critical to the function of TLOs. PNAd-expressing 
blood vessels lined by flat ECs are found inside cancer-induced 
ectopic lymphoid aggregates that are not organized into distinct 
T/B cell areas. These could represent immature HEV-containing 
structures in the process of forming TLOs, or TLOs that are dis-
tintegrating during the resolution of chronic inflammation (113). 
Interestingly, PNAd-expressing blood vessels that form follow-
ing depletion of Foxp3+ regulatory T cells from cancer-bearing 
mice are not associated with histologically distinct, lymphoid 
cell aggregates (114) which indicates that HEV neogenesis can 
precede lymphoid neo-organogenesis. The development of 
HEV in the absence of full-blown TLOs correlates with cancer 
regression in this experimental model highlighting the important 
role of HEV in controlling immunity to cancers. Interestingly 
gp38+ (podoplanin) stromal cells are induced locally by CD11b+ 
myeloid cells recruited to inflamed skin of mice, recapitulating 
the earliest stages of lymphoid stromal cell development, but 
whether CD11b+ myeloid cells drive the development HEV and/
or TLOs in chronic inflammation is not known (17).
How HEVs form during ongoing chronic diseases is difficult 
to dissect but insights to the stimuli and signaling pathways 
that control HEV neogenesis and function have come from 
experimental studies in mice. In experimental animals, organ-
ized lymphocytic infiltrates containing PNAd-expressing blood 
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vessels develop in exocrine tissue of the pancreas and thyroid 
in response to ectopic expression of homeostatic chemokines 
and cytokines that control LN development (115–118) and 
virus-induced autoantibody production in the salivary gland 
(119). However, as found in chronic diseases, the size, location, 
and composition of lymphoid infiltrates that develop at ectopic 
sites vary depending on the stimulus. For example, when LTα 
is expressed in pancreatic β cells PNAd expressing blood vessels 
are found inside the small lymphoid infiltrates that form around 
some islets (120). Development is independent of endogenous 
LTβ and dependent on signaling via the type I TNFR. However, 
the infiltrates comprise mainly memory T cells that express low 
levels of L-selectin, which may be due to the predominantly ablu-
minal expression of PNAd, which is unable to recruit L-selectin 
expressing lymphocytes (118). Co-expression of both LTα and 
LTβ and consequent LTβR signaling in the exocrine pancreas is 
required to develop large, organized lymphoid aggregates that 
contain HEV expressing PNAd at the luminal surface and, as 
in LNs, these ectopic TLOs are highly enriched in L-selectin-
expressing T and B lymphocytes. LTαβ expressing cells other than 
LTis drive TLO formation, such as T and B cells which upregulate 
LTαβ in response to ectopic expression of CCL21 and CXCL13, 
respectively (116). PNAd expressing, structurally distinct HEV 
develop within 5  days of transferring T cells to RAG-deficient 
mice expressing CCL21 under the thyroglubulin promoter and, 
as found in LN, HEV development is dependent on LTαβ–LTβR 
signaling and DCs (117, 121). As in LN, the development of 
PNAd expressing HEV in cytokine or chemokine-induced 
TLOs is stunted in mice deficient in either LTα or LTβ. PNAd-
expressing blood vessels lack the HEV-restricted sulfotransferase 
and, therefore, luminal expression of PNAd, and are lined with 
flat ECs typical of immature HEVs in LN unable to support 
high levels of lymphocyte traffic. The lack of HEV maturation 
in the absence of LTα or LTβ correlates with and, most likely, 
contributes to the reduced size and cellularity of lymphoid 
infiltrates in these mice (118).
The development of PNAd-expressing HEV in mouse models 
of cytokine- or inflammation-induced cancer correlates with 
increased T cell infiltration and priming and reduced tumor 
growth (114, 122, 123). In tumor cell transplant models, PNAd 
expression is induced on tumor blood vessels by infiltrating 
tumor-specific effector CD8+ T cells as well as NK cells (124). 
In marked contrast to HEV development in LN and TLO, PNAd 
expression is not dependent on LTβR signaling but is stimulated 
by CD8+ T and NK cell-derived LTα3 activation of TNFR. 
Interestingly, expression of the arrest chemokine CCL21 is not 
induced by the same stimuli that induce PNAd expression, but 
instead by IFN-γ released by activated T and NK cells. However, 
the tumor-associated HEVs are distinct from conventional 
mature HEVs in LN since PNAd expression is exceptionally low 
and the endothelial lining is flat, rather than the characteristic, 
LTβR-dependent cuboidal morphology found in LNs (50). 
Although comprising <10% of the tumor vascular network and 
lined by flat EC, these PNAd-expressing tumor blood vessels are 
functional in that they recruit naïve, L-selectin-expressing T cells 
from the bloodstream into the tumor where they are activated 
to kill tumor tissue (124). These findings suggest that TNFR 
signaling in ECs stimulates the development of PNAd-expressing 
blood vessels resembling immature HEVs in LNs and that these 
vessels promote anti-tumour immunity by recruiting naïve T cells 
into cancerous tissues. This allows T cell priming and reactivation 
inside solid cancers, thus avoiding the dilution of tumoricidal T 
cells during redistribution from their LN site of priming via the 
efferent lymphatics and bloodstream (123).
The presence of HEV-containing TLO is highly correlated 
with active disease and for persistent infections such as H. pylori, 
TLOs in the gastric mucosa disappear when the infection is 
cleared (125). In the case of solid, vascularized cancers, the 
presence of TLO in resected solid cancers has been correlated 
with prolonged patient outcome following resection of the 
primary cancer in breast cancer (126, 127), melanoma (128, 
129), lung (130), and colorectal cancer, although in the latter 
case the correlation depends on the stage of the disease (131, 
132). In separate studies of lung cancer, mature DC containing 
TLO enriched in CD8+ effector memory T cells or expressing a 
LN-associated chemokine and adhesion molecule gene signature 
have both been correlated with improved patient outcome (133, 
134). Importantly however, the formation of TLO does not always 
indicate improved cancer patient outcome. In virus-induced 
hepatic cellular carcinoma, TLOs provide a cytokine-rich niche, 
which promotes the development and survival of malignant 
hepatocyte progenitors (11). The density of HEV alone was suf-
ficient to predict patient outcome in breast cancer and melanoma 
(9, 10), indicating the critical role that HEVs play in orchestrating 
anticancer immunity. It will be interesting to determine the 
expression of other markers of HEV differentiation such as 
MAdCAM-1, GlyCAM-1, GlcNAc6ST-2, and GlcNAc6ST-1 to 
further understand the precise roles of HEV development and 
maturation in protective immunity to clinical cancers.
Evidence of ongoing immune responses are seen inside TLOs; 
activation-induced cytidine deaminase is active in ectopic germi-
nal centers in salivary glands of Sjorgren’s syndrome patients (5) 
and T cell priming and epitope spreading occur in mouse models of 
multiple sclerosis and cancer (122, 135). In mice lacking all SLOs, 
Moyron-Quiroz and colleagues demonstrated that humoral and 
cellular immune responses develop in TLOs following influenza 
infection (136). The formation of TLO in clinical conditions may, 
therefore, reflect a lack of function in draining secondary LNs, 
which are no longer able to accept incoming antigen or antigen-
presenting cells or that SLOs are operating at maximal capacity. 
The formation of TLOs is thought to exacerbate autoimmune 
diseases, at least in part, because effector lymphocytes generated 
within the target organ will not be diluted out during transit from 
the normal LN site of priming. However, the impact of TLO will 
depend on the nature of the ongoing immune response to the 
autoantigen, pathogen, or cancer antigen, which may be protec-
tive (CD8+ T cells in cancer), inflammatory (Th17 cells in autoim-
munity), or tolerance inducing (Foxp3+ regulatory T cells), and 
this may be regulated by the activation status of PNAd-expressing 
HEVs and additional factors such as chemokines. Further studies 
are required to understand exactly how ectopic HEVs are formed 
and their impact on different types of chronic diseases. Such stud-
ies may reveal therapeutic targets for intervention in autoimmune 
diseases and cancers.
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A Unifying Hypothesis of Hev Neogenesis
Extensive studies of SLOs and TLOs have shown that HEVs 
present as peripheral and/or mucosal addressin expressing 
blood vessels in which the endothelium is either characteristi-
cally cuboidal and filled with transmigrating lymphocytes or 
flat and, although PNAd-positive, lymphocyte-filled pockets 
are absent. Can we reconcile these divergent reports of HEV 
into a single, unifying model of HEV neogenesis in lymphoid 
and non-lymphoid tissues? Clues for this have come from 
studies in which cytokines ectopically expressed in pancreatic 
islets of mice stimulate the development of vascular addressin 
expressing blood vessels. Expression of LTα-induced PNAd and 
MAdCAM-1 on pancreatic blood vessels dependent on signaling 
through TNFR1 but the ECs are flat, do not express the HEV-
restricted sulfotransferase (HEC-6ST/GlcNAc6ST-2) and PNAd 
expression was located to the basolateral EC surface where, in 
LN, it does not support high levels of lymphocyte recruitment. 
Structurally distinct, PNAd-expressing blood vessels, similar 
to HEVs in LN, were only formed when LTα and LTβ were co-
expressed in pancreatic islets (137). Interestingly, LT-α drives the 
development of flat, PNAd-expressing blood vessels in mouse 
models of cancer which, although structurally similar to imma-
ture HEVs in LN, are able to recruit L-selectin-expressing T cells 
from the bloodstream via PNAd+ ligands indicating they are not 
completely immature (124).
LTα and LTαβ activate the classical NF-κB pathway charac-
terized by nuclear translocation of p50–RelA complexes. LTαβ 
also activates the alternative, non-canonical NF-κB pathway 
of NF-κB-inducing kinase (NIK)-dependent activation of IκB 
kinase (IKK)-α and nuclear translocation of p52–RelB complexes 
(138). Non-canonical NF-κB signaling plays a dominant role 
in the formation of HEVs in LNs since blockade of LTβR, but 
not TNFR, leads to loss of several HEV-specific markers such 
as GlyCAM-1, MAdCAM-1, CCL21, and the HEV-restricted 
sulfotransferase, HEC-6ST/GlcNAc6ST-2 (58). In addition, 
PNAd-expressing blood vessels that develop in IKKα(AA) 
mutant mice where non-canonical NF-κB signaling is defective 
lack GlyCAM-1 and HEC-6ST (49). Conversely, mice lacking 
full-length p100 protein, resulting in constitutively active p52, 
develop PNAd-positive HEVs in the spleen (139). The key event 
in non-canonical NF-κB activation is signal-induced protein sta-
bilization of NIK that is normally degraded by a ubiquitin ligase 
complex comprising TRAF2, TRAF3, and cIAP1/2 (140, 141). 
LTβR ligation sequesters this NIK-targeting destruction complex 
leading to NIK accumulation. Importantly, signal-induced NIK 
stability is transient (142), suggesting that continual activation 
of the LTβR is required to maintain functional NIK expression 
levels and hence, sustain the activity of the non-canonical NF-κB 
pathway.
It is proposed that the development of HEVs is dissected into 
at least two distinct stages based on NF-κB signaling in blood 
vessel ECs (Figure  2). The first stage is driven by LTα-TNFR 
classical NF-κB signaling and generates MAdCAM-1-expressing 
HEV lined with flat, PNAd-expressing ECs. The second stage is 
driven by sustained LTβR non-canonical NF-κB signaling and 
induces the development of fully mature, PNAd-expressing 
HEVs lined by HECs and containing lymphocyte-filled pockets. 
However, these two stages may be not always be clearly deline-
ated because there is overlap between classical and non-canonical 
NFκB signaling in blood ECs. For example, classical RelA/NF-κB 
signaling by TNFα, LTα, or LTαβ in EC cultured from human 
and mouse tissues induces expression of MAdCAM-1 protein 
and expression of the gene encoding HEC-6ST, which generates 
the PNAd epitope in LN HEVs (33–35, 143). However, LTβR 
signaling in isolated human EC has not been reported to induce 
the expression of PNAd modified glycoproteins (143). It is known 
that classical NF-κB-dependent signaling in human EC inhibits 
non-canonical NF-κB signaling (144). The outcome of LTβR 
signaling in ECs will, therefore, depend on the balance between 
classical and non-canonical NF-κB signaling. Recent studies 
have demonstrated that endothelial differentiation is regulated 
by components of the basal lamina (145). As in other types of 
postcapillary venule, structural support to the endothelial lining 
of HEV is provided by the basal lamina, which is known to regu-
late NF-κB signaling (146). Further studies on isolated blood ECs 
may identify the stimuli and signaling pathways that stimulate 
the synthesis of HEV-restricted PNAd-modified glycoproteins 
thereby controlling HEV neogenesis.
THeRAPeUTiC STRATeGieS TO 
CONTROL Hev NeOGeNeSiS AND 
FUNCTiON
If HEVs in TLO are critical to exacerbation of autoimmune 
diseases by allowing activation of tissue destroying lymphocytes 
within target tissues, can the development of HEVs be prevented? 
Since HEVs in SLOs are important for generating protective 
immunity to infection any such therapy would need to be targeted 
to TLO. Intuitively, this will require the identification of markers 
or signaling pathways in ectopic HEVs that are not shared by 
HEVs in LN. One candidate is TNFR signaling that is not required 
for the development or maintenance of HEVs in LN (58) but has 
been shown to induce PNAd-expressing ectopic HEVs able to 
recruit naïve T lymphocytes, at least in cancer (124). It is pos-
sible that the success of anti-TNF-α or TNFRII-Ig (Etanercept) 
therapies in rheumatoid arthritis patients may depend, in part, 
on reversing or blocking blood vessel differentiation toward an 
HEV-like phenotype. The formation of HEVs in cancerous tissues 
in the absence of TLO correlates with reduced tumor progression 
in experimental animals; HEV neogenesis may, therefore, be a 
possible therapy to control cancer growth but it is not clear how 
this would be achieved. Clinical and experimental data indicate 
that tumor blood vessels are poor at recruiting cytotoxic, effector 
T lymphocytes and present an immune checkpoint that limits 
effective immunotherapy (147). Several different strategies are 
being considered to achieve this including targeted delivery of 
TNF-α to tumor blood vessels, which may induce the develop-
ment of PNAd-expressing blood vessels although this was not 
determined (148). Approaches to induce HEV-containing TLO 
formation in cancers are also being considered but it is worth 
bearing in mind that TLOs, like SLOs, could be sites of tolerance 
induction and, therefore, may limit effective antitumor immunity. 
The full impact of HEVs and/or TLO may only be revealed when 
FiGURe 2 | The development of ectopic high endothelial venules (Hevs). Top: diagrammatic representation of blood vasculature in non-lymphoid organs and 
the location of postcapillary venules. Bottom (left): blood vessels in acutely inflamed tissues do not express vascular addressins but are able to recruit activated 
lymphoid cells. (Middle) TNFα, LTα, or LTαβ expressing T or NK cells recruited by inflamed blood vessels induce the expression of peripheral node addressin (PNAd) 
(and/or MAdCAM-1) in blood vessels lined with flat endothelial cells (ECs) by stimulating classical NF-κB (RelA) signaling in ECs. (Right) Sustained contact between 
LTαβ expressing activated lymphoid cells and PNAd expressing flat EC induces LTβR-dependent non-canonical NF-κB (RelB) signaling in ECs, which allows the full 
maturation of PNAd-expressing HEV lined with cuboidal ECs filled with transmigrating lymphocytes. It is not known if the recruitment of fibroblast reticular cells into 
the perivascular sheath surrounding HEV is driven by LTβR signaling in ECs or perivascular cells or both.
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highly immunosuppressive cells such as Foxp3+ Tregs or myeloid-
derived suppressor cells are depleted allowing effector T cells to 
exit TLO, infiltrate, and kill cancerous tissues (114, 149, 150). It 
will be important to determine which immune cells are recruited 
by cancer-associated HEVs to dissect their impact on cancer 
immunity. Further studies are required to determine the extent 
and role of HEV development in clinical cancers.
AUTHOR CONTRiBUTiONS
The author confirms being the sole contributor of this work and 
approved it for publication.
ACKNOwLeDGMeNTS
I thank Mike May, Mark Coles, Jens Stein, Diana Costa Bento, 
and Emily Colbeck for stimulating discussions about HEV; Julia 
Ohme for images of vascular addressin expression; and Janice 
Sharp for the figures.
FUNDiNG
AA is supported by project grants from the Wellcome Trust 
(094511/Z/10/Z) and the Medical Research Council UK (MR/
L008742/1).
ReFeReNCeS
1. Masopust D, Schenkel JM. The integration of T cell migration, differenti-
ation and function. Nat Rev Immunol (2013) 13(5):309–20. doi:10.1038/
nri3442 
2. Fletcher AL, Malhotra D, Turley SJ. Lymph node stroma broaden the periph-
eral tolerance paradigm. Trends Immunol (2011) 32(1):12–8. doi:10.1016/j.
it.2010.11.002 
3. Girard JP, Moussion C, Forster R. HEVs, lymphatics and homeostatic immune 
cell trafficking in lymph nodes. Nat Rev Immunol (2012) 12(11):762–73. 
doi:10.1038/nri3298 
4. Drayton DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ devel-
opment: from ontogeny to neogenesis. Nat Immunol (2006) 7(4):344–53. 
doi:10.1038/ni1330 
5. Bombardieri M, Barone F, Humby F, Kelly S, McGurk M, Morgan P, et al. 
Activation-induced cytidine deaminase expression in follicular dendritic cell 
12
Ager Blood Vessels and Lymphoid Organs
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 45
networks and interfollicular large B cells supports functionality of ectopic 
lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma 
in Sjogren’s syndrome. J Immunol (2007) 179(7):4929–38. doi:10.4049/
jimmunol.179.7.4929 
6. Astorri E, Bombardieri M, Gabba S, Peakman M, Pozzilli P, Pitzalis C. 
Evolution of ectopic lymphoid neogenesis and in  situ autoantibody 
production in autoimmune nonobese diabetic mice: cellular and molec-
ular characterization of tertiary lymphoid structures in pancreatic islets. 
J Immunol (2010) 185(6):3359–68. doi:10.4049/jimmunol.1001836 
7. Lee Y, Chin RK, Christiansen P, Sun Y, Tumanov AV, Wang J, et  al. 
Recruitment and activation of naive T cells in the islets by lymphotoxin 
beta receptor-dependent tertiary lymphoid structure. Immunity (2006) 
25(3):499–509. doi:10.1016/j.immuni.2006.06.016 
8. Sautes-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman 
WH, et  al. Tertiary lymphoid structures in cancers: prognostic value, 
regulation, and manipulation for therapeutic intervention. Front Immunol 
(2016) 7:407. doi:10.3389/fimmu.2016.00407 
9. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, 
et  al. Human solid tumors contain high endothelial venules: association 
with T- and B-lymphocyte infiltration and favorable prognosis in breast 
cancer. Cancer Res (2011) 71(17):5678–87. doi:10.1158/0008-5472.CAN- 
11-0431 
10. Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P, et al. 
High endothelial venules (HEVs) in human melanoma lesions: major 
gateways for tumor-infiltrating lymphocytes. Oncoimmunology (2012) 
1(6):829–39. doi:10.4161/onci.20492 
11. Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, et  al. Ectopic 
lymphoid structures function as microniches for tumor progenitor 
cells in hepatocellular carcinoma. Nat Immunol (2015) 16(12):1235–44. 
doi:10.1038/ni.3290 
12. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni 
M, et  al. Regression of primary low-grade B-cell gastric lymphoma of 
mucosa-associated lymphoid tissue type after eradication of Helicobacter 
pylori. Lancet (1993) 342(8871):575–7. doi:10.1016/0140-6736(93)91409-F 
13. Kobayashi M, Lee H, Schaffer L, Gilmartin TJ, Head SR, Takaishi S, et al. 
A distinctive set of genes is upregulated during the inflammation-carcinoma 
sequence in mouse stomach infected by Helicobacter felis. J Histochem 
Cytochem (2007) 55(3):263–74. doi:10.1369/jhc.6A7097.2006 
14. van de Pavert SA, Mebius RE. New insights into the development of 
lymphoid tissues. Nat Rev Immunol (2010) 10(9):664–74. doi:10.1038/ 
nri2832 
15. Randall TD, Carragher DM, Rangel-Moreno J. Development of secondary 
lymphoid organs. Annu Rev Immunol (2008) 26:627–50. doi:10.1146/
annurev.immunol.26.021607.090257 
16. Blum KS, Pabst R. Keystones in lymph node development. J Anat (2006) 
209(5):585–95. doi:10.1111/j.1469-7580.2006.00650.x 
17. Peduto L, Dulauroy S, Lochner M, Spath GF, Morales MA, Cumano A, 
et  al. Inflammation recapitulates the ontogeny of lymphoid stromal cells. 
J Immunol (2009) 182(9):5789–99. doi:10.4049/jimmunol.0803974 
18. Hendricks HR, Eestermans IL. Disappearance and reappearance of high 
endothelial venules and immigrating lymphocytes in lymph nodes deprived 
of afferent lymphatic vessels: a possible regulatory role of macrophages 
in lymphocyte migration. Eur J Immunol (1983) 13:663–9. doi:10.1002/
eji.1830130811 
19. Mebius RE, Streeter PR, Breve J, Duijvestijn AM, Kraal G. The influence 
of afferent lymphatic vessel interruption on vascular addressin expression. 
J Cell Biol (1991) 115(1):85–95. doi:10.1083/jcb.115.1.85 
20. Lacorre DA, Baekkevold ES, Garrido I, Brandtzaeg P, Haraldsen G, Amalric 
F, et  al. Plasticity of endothelial cells: rapid dedifferentiation of freshly 
isolated high endothelial venule endothelial cells outside the lymphoid 
tissue microenvironment. Blood (2004) 103(11):4164–72. doi:10.1182/
blood-2003-10-3537 
21. Mebius RE, Streeter PR, Michie S, Butcher EC, Weissman IL. A developmen-
tal switch in lymphocyte homing receptor and endothelial vascular addressin 
expression regulates lymphocyte homing and permits CD4+ CD3- cells to 
colonize lymph nodes. Proc Natl Acad Sci U S A (1996) 93(20):11019–24. 
doi:10.1073/pnas.93.20.11019 
22. Mebius RE. Organogenesis of lymphoid tissues. Nat Rev Immunol (2003) 
3(4):292–303. doi:10.1038/nri1054 
23. Zhang Z, Li J, Zheng W, Zhao G, Zhang H, Wang X, et al. Peripheral lym-
phoid volume expansion and maintenance are controlled by gut microbiota 
via RALDH+ dendritic cells. Immunity (2016) 44(2):330–42. doi:10.1016/j.
immuni.2016.01.004 
24. Moussion C, Girard JP. Dendritic cells control lymphocyte entry to lymph 
nodes through high endothelial venules. Nature (2011) 479(7374):542–6. 
doi:10.1038/nature10540 
25. Wigle JT, Oliver G. Prox1 function is required for the development of 
the murine lymphatic system. Cell (1999) 98(6):769–78. doi:10.1016/
S0092-8674(00)81511-1 
26. Mebius RE, Rennert P, Weissman IL. Developing lymph nodes collect 
CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and fol-
licular cells but not T or B cells. Immunity (1997) 7(4):493–504. doi:10.1016/
S1074-7613(00)80371-4 
27. Veiga-Fernandes H, Coles MC, Foster KE, Patel A, Williams A, Natarajan 
D, et  al. Tyrosine kinase receptor RET is a key regulator of Peyer’s patch 
organogenesis. Nature (2007) 446(7135):547–51. doi:10.1038/nature05597 
28. Hashi H, Yoshida H, Honda K, Fraser S, Kubo H, Awane M, et  al. 
Compartmentalization of Peyer’s patch anlagen before lymphocyte entry. 
J Immunol (2001) 166(6):3702–9. doi:10.4049/jimmunol.166.6.3702 
29. Gretz JE, Norbury CC, Anderson AO, Proudfoot AE, Shaw S. Lymph-
borne chemokines and other low molecular weight molecules reach high 
endothelial venules via specialized conduits while a functional barrier limits 
access to the lymphocyte microenvironments in lymph node cortex. J Exp 
Med (2000) 192(10):1425–40. doi:10.1084/jem.192.10.1425 
30. Pruenster M, Mudde L, Bombosi P, Dimitrova S, Zsak M, Middleton J, 
et  al. The Duffy antigen receptor for chemokines transports chemokines 
and supports their promigratory activity. Nat Immunol (2009) 10(1):101–8. 
doi:10.1038/ni.1675
31. Palframan RT, Jung S, Cheng CY, Weninger W, Luo Y, Dorf M, et  al. 
Inflammatory chemokine transport and presentation in HEV: a remote 
control mechanism for monocyte recruitment to lymph nodes in inflamed 
tissues. J Exp Med (2001) 194(9):1361–73. doi:10.1084/jem.194.9.1361 
32. Baekkevold ES, Yamanaka T, Palframan RT, Carlsen HS, Reinholt FP, von 
Andrian UH, et al. The CCR7 ligand ELC (CCL19) is transcytosed in high 
endothelial venules and mediates T cell recruitment. J Exp Med (2001) 
193(9):1105–12. doi:10.1084/jem.193.9.1105 
33. Sikorski EE, Hallmann R, Berg EL, Butcher EC. The Peyer’s patch high 
endothelial receptor for lymphocytes, the mucosal vascular addressin, is 
induced on a murine endothelial cell line by tumor necrosis factor-alpha 
and IL-1. J Immunol (1993) 151(10):5239–50. 
34. Takeuchi M, Baichwal VR. Induction of the gene encoding mucosal vas-
cular addressin cell adhesion molecule 1 by tumor necrosis factor alpha 
is mediated by NF-kappa B proteins. Proc Natl Acad Sci U S A (1995) 
92(8):3561–5. doi:10.1073/pnas.92.8.3561 
35. Cuff CA, Schwartz J, Bergman CM, Russell KS, Bender JR, Ruddle NH. 
Lymphotoxin alpha3 induces chemokines and adhesion molecules: insight 
into the role of LT alpha in inflammation and lymphoid organ development. 
J Immunol (1998) 161(12):6853–60. 
36. Pabst O, Forster R, Lipp M, Engel H, Arnold HH. NKX2.3 is required for 
MAdCAM-1 expression and homing of lymphocytes in spleen and muco-
sa-associated lymphoid tissue. EMBO J (2000) 19(9):2015–23. doi:10.1093/
emboj/19.9.2015 
37. Schippers A, Leuker C, Pabst O, Kochut A, Prochnow B, Gruber AD, 
et  al. Mucosal addressin cell-adhesion molecule-1 controls plasma-cell 
migration and function in the small intestine of mice. Gastroenterology 
(2009) 137(3):924–33. doi:10.1053/j.gastro.2009.05.039 
38. Gurtner GC, Davis V, Li H, McCoy MJ, Sharpe A, Cybulsky MI. Targeted 
disruption of the murine VCAM1 gene: essential role of VCAM-1 in 
chorioallantoic fusion and placentation. Genes Dev (1995) 9(1):1–14. 
doi:10.1101/gad.9.1.1 
39. Xu H, Gonzalo JA, St Pierre Y, Williams IR, Kupper TS, Cotran RS, et al. 
Leukocytosis and resistance to septic shock in intercellular adhesion mol-
ecule 1-deficient mice. J Exp Med (1994) 180(1):95–109. doi:10.1084/jem. 
180.1.95 
40. De Togni P, Goellner J, Ruddle NH, Streeter PR, Fick A, Mariathasan S, et al. 
Abnormal development of peripheral lymphoid organs in mice deficient 
in lymphotoxin. Science (1994) 264(5159):703–7. doi:10.1126/science. 
8171322 
13
Ager Blood Vessels and Lymphoid Organs
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 45
41. Rennert PD, James D, Mackay F, Browning JL, Hochman PS. Lymph node 
genesis is induced by signaling through the lymphotoxin beta receptor. 
Immunity (1998) 9(1):71–9. doi:10.1016/S1074-7613(00)80589-0 
42. Rennert PD, Browning JL, Mebius R, Mackay F, Hochman PS. Surface 
lymphotoxin alpha/beta complex is required for the development of periph-
eral lymphoid organs. J Exp Med (1996) 184(5):1999–2006. doi:10.1084/
jem.184.5.1999 
43. Lai L, Bohnsack BL, Niederreither K, Hirschi KK. Retinoic acid regulates 
endothelial cell proliferation during vasculogenesis. Development (2003) 
130(26):6465–74. doi:10.1242/dev.00887 
44. Rennert PD, Browning JL, Hochman PS. Selective disruption of lymphotoxin 
ligands reveals a novel set of mucosal lymph nodes and unique effects 
on lymph node cellular organization. Int Immunol (1997) 9(11):1627–39. 
doi:10.1093/intimm/9.11.1627 
45. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 
(1998) 19(2):80–8. doi:10.1016/S0167-5699(97)01197-3 
46. Alcamo E, Hacohen N, Schulte LC, Rennert PD, Hynes RO, Baltimore D. 
Requirement for the NF-kappaB family member RelA in the development of 
secondary lymphoid organs. J Exp Med (2002) 195(2):233–44. doi:10.1084/
jem.20011885 
47. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck RP, et  al. 
Multiorgan inflammation and hematopoietic abnormalities in mice with a 
targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 
(1995) 80(2):331–40. doi:10.1016/0092-8674(95)90416-6 
48. Carragher D, Johal R, Button A, White A, Eliopoulos A, Jenkinson E, 
et  al. A stroma-derived defect in NF-kappaB2-/- mice causes impaired 
lymph node development and lymphocyte recruitment. J Immunol (2004) 
173(4):2271–9. doi:10.4049/jimmunol.173.4.2271 
49. Drayton DL, Bonizzi G, Ying X, Liao S, Karin M, Ruddle NH. I kappa 
B kinase complex alpha kinase activity controls chemokine and high 
endothelial venule gene expression in lymph nodes and nasal-associ-
ated lymphoid tissue. J Immunol (2004) 173(10):6161–8. doi:10.4049/ 
jimmunol.173.10.6161 
50. Onder L, Danuser R, Scandella E, Firner S, Chai Q, Hehlgans T, et  al. 
Endothelial cell-specific lymphotoxin-beta receptor signaling is critical 
for lymph node and high endothelial venule formation. J Exp Med (2013) 
210(3):465–73. doi:10.1084/jem.20121462 
51. Rosen SD. Ligands for L-selectin: homing, inflammation, and 
beyond. Annu Rev Immunol (2004) 22:129–56. doi:10.1146/annurev.
immunol.21.090501.080131 
52. Mitoma J, Bao X, Petryanik B, Schaerli P, Gauguet JM, Yu SY, et al. Critical 
functions of N-glycans in L-selectin-mediated lymphocyte homing and 
recruitment. Nat Immunol (2007) 8(4):409–18. doi:10.1038/ni1442 
53. Streeter PR, Rouse BT, Butcher EC. Immunohistologic and functional 
characterization of a vascular addressin involved in lymphocyte homing 
into peripheral lymph nodes. J Cell Biol (1988) 107(5):1853–62. doi:10.1083/
jcb.107.5.1853 
54. Streeter PR, Berg EL, Rouse BT, Bargatze RF, Butcher EC. A tissue-specific 
endothelial cell molecule involved in lymphocyte homing. Nature (1988) 
331(6151):41–6. doi:10.1038/331041a0 
55. Kellermayer Z, Labadi A, Czompoly T, Arnold HH, Balogh P. 
Absence of Nkx2-3 homeodomain transcription factor induces the 
formation of LYVE-1-positive endothelial cysts without lymphatic 
commitment in the spleen. J Histochem Cytochem (2011) 59(7):690–700. 
doi:10.1369/0022155411410061 
56. Anderson AO, Shaw S. T cell adhesion to endothelium: the FRC conduit 
system and other anatomic and molecular features which facilitate the 
adhesion cascade in lymph node. Semin Immunol (1993) 5(4):271–82. 
doi:10.1006/smim.1993.1031 
57. Swarte VV, Joziasse DH, Van den Eijnden DH, Petryniak B, Lowe JB, Kraal 
G, et  al. Regulation of fucosyltransferase-VII expression in peripheral 
lymph node high endothelial venules. Eur J Immunol (1998) 28(10):3040–7. 
doi:10.1002/(SICI)1521-4141(199810)28:10<3040::AID-IMMU3040> 
3.0.CO;2-5 
58. Browning JL, Allaire N, Ngam-Ek A, Notidis E, Hunt J, Perrin S, et  al. 
Lymphotoxin-beta receptor signaling is required for the homeostatic con-
trol of HEV differentiation and function. Immunity (2005) 23(5):539–50. 
doi:10.1016/j.immuni.2005.10.002 
59. Lindquist RL, Shakhar G, Dudziak D, Wardemann H, Eisenreich T, Dustin 
ML, et al. Visualizing dendritic cell networks in vivo. Nat Immunol (2004) 
5(12):1243–50. doi:10.1038/ni1139 
60. Kissenpfennig A, Henri S, Dubois B, Laplace-Builhe C, Perrin P, Romani N, 
et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic 
cells colonize lymph node areas distinct from slower migrating Langerhans 
cells. Immunity (2005) 22(5):643–54. doi:10.1016/j.immuni.2005.04.004 
61. Bajenoff M, Granjeaud S, Guerder S. The strategy of T cell antigen-presenting 
cell encounter in antigen-draining lymph nodes revealed by imaging of 
initial T cell activation. J Exp Med (2003) 198(5):715–24. doi:10.1084/
jem.20030167 
62. Randolph GJ, Ochando J, Partida-Sanchez S. Migration of dendritic cell 
subsets and their precursors. Annu Rev Immunol (2008) 26:293–316. 
doi:10.1146/annurev.immunol.26.021607.090254 
63. Choi JH, Do Y, Cheong C, Koh H, Boscardin SB, Oh YS, et al. Identification 
of antigen-presenting dendritic cells in mouse aorta and cardiac valves. 
J Exp Med (2009) 206(3):497–505. doi:10.1084/jem.20082129 
64. Wendland M, Willenzon S, Kocks J, Davalos-Misslitz AC, Hammerschmidt 
SI, Schumann K, et al. Lymph node T cell homeostasis relies on steady state 
homing of dendritic cells. Immunity (2011) 35(6):945–57. doi:10.1016/j.
immuni.2011.10.017 
65. Chyou S, Ekland EH, Carpenter AC, Tzeng TC, Tian S, Michaud M, et al. 
Fibroblast-type reticular stromal cells regulate the lymph node vasculature. 
J Immunol (2008) 181(6):3887–96. doi:10.4049/jimmunol.181.6.3887 
66. Webster B, Ekland EH, Agle LM, Chyou S, Ruggieri R, Lu TT. Regulation 
of lymph node vascular growth by dendritic cells. J Exp Med (2006) 
203(8):1903–13. doi:10.1084/jem.20052272 
67. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of 
inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 
(2007) 7(9):678–89. doi:10.1038/nri2156 
68. Steiniger B, Timphus EM, Barth PJ. The splenic marginal zone in humans 
and rodents: an enigmatic compartment and its inhabitants. Histochem Cell 
Biol (2006) 126(6):641–8. doi:10.1007/s00418-006-0210-5 
69. Lee M, Kiefel H, LaJevic MD, Macauley MS, Kawashima H, O’Hara E, et al. 
Transcriptional programs of lymphoid tissue capillary and high endothelium 
reveal control mechanisms for lymphocyte homing. Nat Immunol (2014) 
15(10):982–95. doi:10.1038/ni.2983 
70. Warnock RA, Askari S, Butcher EC, von Andrian UH. Molecular mecha-
nisms of lymphocyte homing to peripheral lymph nodes. J Exp Med (1998) 
187(2):205–16. doi:10.1084/jem.187.2.205 
71. M’Rini C, Cheng G, Schweitzer C, Cavanagh LL, Palframan RT, Mempel TR, 
et al. A novel endothelial L-selectin ligand activity in lymph node medulla 
that is regulated by alpha(1,3)-fucosyltransferase-IV.[see comment]. J Exp 
Med (2003) 198(9):1301–12. doi:10.1084/jem.20030182 
72. Picker LJ, Butcher EC. Physiological and molecular mechanisms of lympho-
cyte homing. Annu Rev Immunol (1992) 10:561–91. doi:10.1146/annurev.
iy.10.040192.003021 
73. Gauguet JM, Bonaiso R, von Andrian UH. High endothelial venules. In: Aird 
WC, editor. Endothelial BioMedcine. New York, NY: Cambridge University 
Press (2007). p. 1568–88.
74. Ager A, Coles MC, Stein JV. Development of lymph node circulation 
and homing mechanisms. In: Balogh P, editor. Developmental Biology of 
Lymphoid Organs. Berlin: Springer-Verlag (2010). p. 75–94.
75. Michie SA, Streeter PR, Bolt PA, Butcher EC, Picker LJ. The human 
peripheral lymph node vascular addressin. An inducible endothelial antigen 
involved in lymphocyte homing. Am J Pathol (1993) 143(6):1688–98. 
76. Abitorabi MA, Mackay CR, Jerome EH, Osorio O, Butcher EC, Erle 
DJ. Differential expression of homing molecules on recirculating lym-
phocytes from sheep gut, peripheral, and lung lymph. J Immunol (1996) 
156(9):3111–7. 
77. Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, 
et al. Human mucosal addressin cell adhesion molecule-1 is preferentially 
expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 
(1997) 151(1):97–110. 
78. Pullen N, Molloy E, Carter D, Syntin P, Clemo F, Finco-Kent D, et  al. 
Pharmacological characterization of PF-00547659, an anti-human 
MAdCAM monoclonal antibody. Br J Pharmacol (2009) 157(2):281–93. 
doi:10.1111/j.1476-5381.2009.00137.x 
14
Ager Blood Vessels and Lymphoid Organs
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 45
79. Salmi M, Alanen K, Grenman S, Briskin M, Butcher EC, Jalkanen S. 
Immune cell trafficking in uterus and early life is dominated by the mucosal 
addressin MAdCAM-1 in humans. Gastroenterology (2001) 121(4):853–64. 
doi:10.1053/gast.2001.27968 
80. Arbones ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, Otten G, 
et  al. Lymphocyte homing and leukocyte rolling and migration are 
impaired in L-selectin-deficient mice. Immunity (1994) 1(4):247–60. 
doi:10.1016/1074-7613(94)90076-0 
81. Fossum S, Smith ME, Ford WL. The migration of lymphocytes across special-
ized vascular endothelium VII. The migration of T and B lymphocytes from 
the blood of the athymic, nude rat. Scand J Immunol (1983) 17(6):539–50. 
doi:10.1111/j.1365-3083.1983.tb00822.x 
82. Bajenoff M, Egen JG, Koo LY, Laugier JP, Brau F, Glaichenhaus N, et  al. 
Stromal cell networks regulate lymphocyte entry, migration, and territo-
riality in lymph nodes. Immunity (2006) 25(6):989–1001. doi:10.1016/j.
immuni.2006.10.011 
83. Boscacci RT, Pfeiffer F, Gollmer K, Sevilla AI, Martin AM, Soriano SF, 
et  al. Comprehensive analysis of lymph node stroma-expressed Ig super-
family members reveals redundant and nonredundant roles for ICAM-1, 
ICAM-2, and VCAM-1 in lymphocyte homing. Blood (2010) 116(6):915–25. 
doi:10.1182/blood-2009-11-254334 
84. Schoefl GI. The migration of lymphocytes across the vascular endothelium 
in lymphoid tissue. A reexamination. J Exp Med (1972) 136(3):568–88. 
doi:10.1084/jem.136.3.568 
85. Engelhardt B, Wolburg H. Mini-review: transendothelial migration of 
leukocytes: through the front door or around the side of the house? Eur 
J Immunol (2004) 34(11):2955–63. doi:10.1002/eji.200425327 
86. Mionnet C, Sanos SL, Mondor I, Jorquera A, Laugier JP, Germain RN, et al. 
High endothelial venules as traffic control points maintaining lymphocyte 
population homeostasis in lymph nodes. Blood (2011) 118(23):6115–22. 
doi:10.1182/blood-2011-07-367409 
87. Faveeuw C, Preece G, Ager A. Transendothelial migration of lymphocytes 
across high endothelial venules into lymph nodes is affected by metallopro-
teinases. Blood (2001) 98(3):688–95. doi:10.1182/blood.V98.3.688 
88. Sainte-Marie G, Peng FS. Dilatation of high endothelial venules in com-
partments of rat lymph nodes with abundant cortical mast cells. J Anat 
(1991) 174:163–70. 
89. Belisle C, Sainte-Marie G. The narrowing of high endothelial venules 
of the rat lymph node. Anat Rec (1985) 211(2):184–91. doi:10.1002/ar. 
1092110210 
90. Campbell FR. Intercellular contacts of lymphocytes during migration across 
high-endothelial venules of lymph nodes. An electron microscopic study. 
Anat Rec (1983) 207(4):643–52. doi:10.1002/ar.1092070413 
91. Barreiro O, Yanez-Mo M, Serrador JM, Montoya MC, Vicente-Manzanares 
M, Tejedor R, et  al. Dynamic interaction of VCAM-1 and ICAM-1 with 
moesin and ezrin in a novel endothelial docking structure for adherent 
leukocytes. J Cell Biol (2002) 157(7):1233–45. doi:10.1083/jcb.200112126 
92. Carman CV, Springer TA. A transmigratory cup in leukocyte diapedesis 
both through individual vascular endothelial cells and between them. J Cell 
Biol (2004) 167(2):377–88. doi:10.1083/jcb.200404129 
93. Pfeiffer F, Kumar V, Butz S, Vestweber D, Imhof BA, Stein JV, et al. Distinct 
molecular composition of blood and lymphatic vascular endothelial cell 
junctions establishes specific functional barriers within the peripheral lymph 
node. Eur J Immunol (2008) 38(8):2142–55. doi:10.1002/eji.200838140 
94. Ager A, May MJ. Understanding high endothelial venules: lessons for 
cancer immunology. Oncoimmunology (2015) 4(6):e1008791. doi:10.1080
/2162402X.2015.1008791 
95. Halin C, Scimone ML, Bonasio R, Gauguet JM, Mempel TR, Quackenbush 
E, et  al. The S1P-analog FTY720 differentially modulates T-cell homing 
via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral 
lymph nodes but not in Peyer patches. Blood (2005) 106(4):1314–22. 
doi:10.1182/blood-2004-09-3687 
96. Hourihan H, Allen TD, Ager A. Lymphocyte migration across high endo-
thelium is associated with increases in alpha 4 beta 1 integrin (VLA-4) 
affinity. J Cell Sci (1993) 104(Pt 4):1049–59. 
97. Klinger A, Gebert A, Bieber K, Kalies K, Ager A, Bell EB, et  al. Cyclical 
expression of L-selectin (CD62L) by recirculating T cells. Int Immunol (2009) 
21(4):443–55. doi:10.1093/intimm/dxp012 
98. Galkina E, Tanousis K, Preece G, Tolaini M, Kioussis D, Florey O, et  al. 
L-selectin shedding does not regulate constitutive T cell trafficking but 
controls the migration pathways of antigen-activated T lymphocytes. J Exp 
Med (2003) 198(9):1323–35. doi:10.1084/jem.20030485 
99. Rzeniewicz K, Newe A, Rey Gallardo A, Davies J, Holt MR, Patel A, et al. 
L-selectin shedding is activated specifically within transmigrating pseudo-
pods of monocytes to regulate cell polarity in vitro. Proc Natl Acad Sci U 
S A (2015) 112(12):E1461–70. doi:10.1073/pnas.1417100112 
100. Hickey MJ, Forster M, Mitchell D, Kaur J, De Caigny C, Kubes P. L-selectin 
facilitates emigration and extravascular locomotion of leukocytes during 
acute inflammatory responses in vivo. J Immunol (2000) 165(12):7164–70. 
doi:10.4049/jimmunol.165.12.7164 
101. Bai Z, Cai L, Umemoto E, Takeda A, Tohya K, Komai Y, et al. Constitutive 
lymphocyte transmigration across the basal lamina of high endothelial 
venules is regulated by the autotaxin/lysophosphatidic acid axis. J Immunol 
(2013) 190(5):2036–48. doi:10.4049/jimmunol.1202025 
102. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD. Autotaxin, 
an ectoenzyme that produces lysophosphatidic acid, promotes the entry 
of lymphocytes into secondary lymphoid organs. Nat Immunol (2008) 
9(4):415–23. doi:10.1038/ni1573 
103. Soderberg KA, Payne GW, Sato A, Medzhitov R, Segal SS, Iwasaki A. 
Innate control of adaptive immunity via remodeling of lymph node feed 
arteriole. Proc Natl Acad Sci U S A (2005) 102(45):16315–20. doi:10.1073/
pnas.0506190102 
104. Hay JB, Hobbs BB. The flow of blood to lymph nodes and its relation to lym-
phocyte traffic and the immune response. J Exp Med (1977) 145(1):31–44. 
doi:10.1084/jem.145.1.31 
105. Kumar V, Scandella E, Danuser R, Onder L, Nitschke M, Fukui Y, et  al. 
Global lymphoid tissue remodeling during a viral infection is orchestrated 
by a B cell-lymphotoxin-dependent pathway. Blood (2010) 115(23):4725–33. 
doi:10.1182/blood-2009-10-250118 
106. Chyou S, Benahmed F, Chen J, Kumar V, Tian S, Lipp M, et al. Coordinated 
regulation of lymph node vascular-stromal growth first by CD11c+ cells 
and then by T and B cells. J Immunol (2011) 187(11):5558–67. doi:10.4049/
jimmunol.1101724 
107. Liao S, Ruddle NH. Synchrony of high endothelial venules and lymphatic 
vessels revealed by immunization. J Immunol (2006) 177(5):3369–79. 
doi:10.4049/jimmunol.177.5.3369 
108. Sawa S, Cherrier M, Lochner M, Satoh-Takayama N, Fehling HJ, Langa F, 
et al. Lineage relationship analysis of RORgammat+ innate lymphoid cells. 
Science (2010) 330(6004):665–9. doi:10.1126/science.1194597 
109. Scandella E, Bolinger B, Lattmann E, Miller S, Favre S, Littman DR, et al. 
Restoration of lymphoid organ integrity through the interaction of lymphoid 
tissue-inducer cells with stroma of the T cell zone. Nat Immunol (2008) 
9(6):667–75. doi:10.1038/ni.1605 
110. Mueller SN, Hosiawa-Meagher KA, Konieczny BT, Sullivan BM, Bachmann 
MF, Locksley RM, et al. Regulation of homeostatic chemokine expression and 
cell trafficking during immune responses. Science (2007) 317(5838):670–4. 
doi:10.1126/science.1144830 
111. Tzeng TC, Chyou S, Tian S, Webster B, Carpenter AC, Guaiquil VH, 
et  al. CD11c(hi) dendritic cells regulate the re-establishment of vascular 
quiescence and stabilization after immune stimulation of lymph nodes. 
J Immunol (2010) 184(8):4247–57. doi:10.4049/jimmunol.0902914 
112. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like 
structures in infection, cancer and autoimmunity. Nat Rev Immunol (2014) 
14(7):447–62. doi:10.1038/nri3700 
113. Cipponi A, Mercier M, Seremet T, Baurain JF, Theate I, van den Oord 
J, et  al. Neogenesis of lymphoid structures and antibody responses occur 
in human melanoma metastases. Cancer Res (2012) 72(16):3997–4007. 
doi:10.1158/0008-5472.CAN-12-1377 
114. Hindley JP, Jones E, Smart K, Bridgeman H, Lauder SN, Ondondo B, et al. 
T-cell trafficking facilitated by high endothelial venules is required for tumor 
control after regulatory T-cell depletion. Cancer Res (2012) 72(21):5473–82. 
doi:10.1158/0008-5472.CAN-12-1912 
115. Luther SA, Lopez T, Bai W, Hanahan D, Cyster JG. BLC expression in 
pancreatic islets causes B cell recruitment and lymphotoxin-dependent 
lymphoid neogenesis. Immunity (2000) 12(5):471–81. doi:10.1016/
S1074-7613(00)80199-5 
15
Ager Blood Vessels and Lymphoid Organs
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 45
116. Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, et  al. 
Differing activities of homeostatic chemokines CCL19, CCL21, and 
CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid 
neogenesis. J Immunol (2002) 169(1):424–33. doi:10.4049/jimmunol.169. 
1.424 
117. Martin AP, Coronel EC, Sano G, Chen SC, Vassileva G, Canasto-Chibuque 
C, et  al. A novel model for lymphocytic infiltration of the thyroid gland 
generated by transgenic expression of the CC chemokine CCL21. J Immunol 
(2004) 173(8):4791–8. doi:10.4049/jimmunol.173.8.4791 
118. Drayton DL, Ying X, Lee J, Lesslauer W, Ruddle NH. Ectopic LT alpha 
beta directs lymphoid organ neogenesis with concomitant expression of 
peripheral node addressin and a HEV-restricted sulfotransferase. J Exp Med 
(2003) 197(9):1153–63. doi:10.1084/jem.20021761 
119. Barone F, Nayar S, Campos J, Cloake T, Withers DR, Toellner KM, et  al. 
IL-22 regulates lymphoid chemokine production and assembly of tertiary 
lymphoid organs. Proc Natl Acad Sci U S A (2015) 112(35):11024–9. 
doi:10.1073/pnas.1503315112 
120. Sacca R, Cuff CA, Lesslauer W, Ruddle NH. Differential activities of 
secreted lymphotoxin-alpha3 and membrane lymphotoxin-alpha1beta2 
in lymphotoxin-induced inflammation: critical role of TNF receptor 1 
signaling. J Immunol (1998) 160(1):485–91. 
121. Marinkovic T, Garin A, Yokota Y, Fu YX, Ruddle NH, Furtado GC, et  al. 
Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the 
development of tertiary lymphoid structures in the thyroid. J Clin Invest 
(2006) 116(10):2622–32. doi:10.1172/JCI28993 
122. Schrama D, thor Straten P, Fischer WH, McLellan AD, Brocker EB, 
Reisfeld RA, et  al. Targeting of lymphotoxin-alpha to the tumor elicits 
an efficient immune response associated with induction of peripheral 
lymphoid-like tissue. Immunity (2001) 14(2):111–21. doi:10.1016/S1074- 
7613(01)00094-2 
123. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, et  al. Priming of naive T 
cells inside tumors leads to eradication of established tumors. Nat Immunol 
(2004) 5(2):141–9. doi:10.1038/ni1029 
124. Peske JD, Thompson ED, Gemta L, Baylis RA, Fu YX, Engelhard VH. Effector 
lymphocyte-induced lymph node-like vasculature enables naive T-cell entry 
into tumours and enhanced anti-tumour immunity. Nat Commun (2015) 
6:7114. doi:10.1038/ncomms8114 
125. Genta RM, Hamner HW. The significance of lymphoid follicles in the 
interpretation of gastric biopsy specimens. Arch Pathol Lab Med (1994) 
118(7):740–3. 
126. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et  al. 
CD4(+) follicular helper T cell infiltration predicts breast cancer survival. 
J Clin Invest (2013) 123(7):2873–92. doi:10.1172/JCI67428 
127. Lee HJ, Park IA, Song IH, Shin SJ, Kim JY, Yu JH, et al. Tertiary lymphoid 
structures: prognostic significance and relationship with tumour-infil-
trating lymphocytes in triple-negative breast cancer. J Clin Pathol (2016) 
69(5):422–30. doi:10.1136/jclinpath-2015-203089 
128. Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et  al. Density 
of DC-LAMP(+) mature dendritic cells in combination with activated T 
lymphocytes infiltrating primary cutaneous melanoma is a strong indepen-
dent prognostic factor. Cancer Immunol Immunother (2007) 56(9):1459–69. 
doi:10.1007/s00262-007-0286-3 
129. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, 
et  al. 12-Chemokine gene signature identifies lymph node-like structures 
in melanoma: potential for patient selection for immunotherapy? Sci Rep 
(2012) 2:765. doi:10.1038/srep00765 
130. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot 
V, et  al. Long-term survival for patients with non-small-cell lung cancer 
with intratumoral lymphoid structures. J Clin Oncol (2008) 26(27):4410–7. 
doi:10.1200/JCO.2007.15.0284 
131. Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, et  al. 
Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration 
and predicts better prognosis in early-stage colorectal cancers. Clin Cancer 
Res (2014) 20(8):2147–58. doi:10.1158/1078-0432.CCR-13-2590 
132. Bento DC, Jones E, Junaid S, Tull J, Williams GT, Godkin A, et  al. High 
endothelial venules are rare in colorectal cancers but accumulate in extra-tu-
moral areas with disease progression. Oncoimmunology (2015) 4(3):e974374. 
doi:10.4161/2162402X.2014.974374 
133. Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, et al. 
Dendritic cells in tumor-associated tertiary lymphoid structures signal 
a Th1 cytotoxic immune contexture and license the positive prognostic 
value of infiltrating CD8+ T cells. Cancer Res (2014) 74(3):705–15. 
doi:10.1158/0008-5472.CAN-13-1342 
134. de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, 
et  al. Characterization of chemokines and adhesion molecules associated 
with T cell presence in tertiary lymphoid structures in human lung cancer. 
Cancer Res (2011) 71(20):6391–9. doi:10.1158/0008-5472.CAN-11-0952 
135. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope 
spreading initiates in the CNS in two mouse models of multiple sclerosis. 
Nat Med (2005) 11(3):335–9. doi:10.1038/nm1202 
136. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague 
F, Goodrich S, et  al. Role of inducible bronchus associated lymphoid 
tissue (iBALT) in respiratory immunity. Nat Med (2004) 10(9):927–34. 
doi:10.1038/nm1091 
137. Cuff CA, Sacca R, Ruddle NH. Differential induction of adhesion molecule 
and chemokine expression by LTalpha3 and LTalphabeta in inflammation 
elucidates potential mechanisms of mesenteric and peripheral lymph node 
development. J Immunol (1999) 162(10):5965–72. 
138. Sun SC. The noncanonical NF-kappaB pathway. Immunol Rev (2012) 
246(1):125–40. doi:10.1111/j.1600-065X.2011.01088.x 
139. Guo F, Weih D, Meier E, Weih F. Constitutive alternative NF-kappaB 
signaling promotes marginal zone B-cell development but disrupts the 
marginal sinus and induces HEV-like structures in the spleen. Blood (2007) 
110(7):2381–9. doi:10.1182/blood-2007-02-075143 
140. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, et al. 
Noncanonical NF-kappaB activation requires coordinated assembly of a 
regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 
and the kinase NIK. Nat Immunol (2008) 9(12):1371–8. doi:10.1038/ 
ni.1676 
141. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, 
et al. Nonredundant and complementary functions of TRAF2 and TRAF3 
in a ubiquitination cascade that activates NIK-dependent alternative 
NF-kappaB signaling. Nat Immunol (2008) 9(12):1364–70. doi:10.1038/ 
ni.1678 
142. Razani B, Zarnegar B, Ytterberg AJ, Shiba T, Dempsey PW, Ware CF, et al. 
Negative feedback in noncanonical NF-kappaB signaling modulates NIK 
stability through IKKalpha-mediated phosphorylation. Sci Signal (2010) 
3(123):ra41. doi:10.1126/scisignal.2000778 
143. Pablos JL, Santiago B, Tsay D, Singer MS, Palao G, Galindo M, et al. A HEV-
restricted sulfotransferase is expressed in rheumatoid arthritis synovium 
and is induced by lymphotoxin-alpha/beta and TNF-alpha in cultured 
endothelial cells. BMC Immunol (2005) 6:6. doi:10.1186/1471-2172-6-6 
144. Madge LA, May MJ. Classical NF-kappaB activation negatively regulates 
noncanonical NF-kappaB-dependent CXCL12 expression. J Biol Chem 
(2010) 285(49):38069–77. doi:10.1074/jbc.M110.147207 
145. Cooley LS, Handsley MM, Zhou Z, Lafleur MA, Pennington CJ, Thompson 
EW, et al. Reversible transdifferentiation of blood vascular endothelial cells 
to a lymphatic-like phenotype in vitro. J Cell Sci (2010) 123(Pt 21):3808–16. 
doi:10.1242/jcs.064279 
146. Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD, et  al. 
Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of 
gene expression important for angiogenesis and inflammation. Mol Cell Biol 
(2002) 22(16):5912–22. doi:10.1128/MCB.22.16.5912-5922.2002 
147. Ager A, Watson HA, Wehenkel SC, Mohammed RN. Homing to 
solid cancers: a vascular checkpoint in adoptive cell therapy using 
CAR T-cells. Biochem Soc Trans (2016) 44(2):377–85. doi:10.1042/ 
BST20150254 
148. Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani 
G, et  al. Targeting TNF-alpha to neoangiogenic vessels enhances lym-
phocyte infiltration in tumors and increases the therapeutic potential 
of immunotherapy. J Immunol (2012) 188(6):2687–94. doi:10.4049/ 
jimmunol.1101877 
149. Joshi NS, Akama-Garren EH, Lu Y, Lee DY, Chang GP, Li A, et  al. 
Regulatory T cells in tumor-associated tertiary lymphoid structures suppress 
anti-tumor T cell responses. Immunity (2015) 43(3):579–90. doi:10.1016/j.
immuni.2015.08.006 
16
Ager Blood Vessels and Lymphoid Organs
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 45
150. Lanca T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: 
implications for cancer surveillance and immunotherapy. Oncoimmunology 
(2012) 1(5):717–25. doi:10.4161/onci.20068 
Conflict of Interest Statement: The author declares that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Ager. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these 
terms.
